Utama › Kanser Prostat Rintangan Kastra › Washington
Kajian klinikal Kanser Prostat Rintangan Kastra di Washington
6 kajian untuk Kanser Prostat Rintangan Kastra sedang mencari peserta di lokasi di Washington.
Bandar di Washington
Teks kajian rasmi (Bahasa Inggeris)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Fred Hutch Cancer Center Sloan Clinic 2, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- VA Puget Sound Healthcare System, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
- University of Washington, Seattle
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT07164443A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Fred Hutchinson Cancer Center ( Site 0013), Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06863272Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Investigational Site Number: 400, Seattle
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 10 Sep 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 10 Ogo 2026 · NCT06067841Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.